Elevated levels of oxidative stress in tamoxifen resistant breast cancer have been previously reported [27], which we postulate may correlate with increased PARP1 expression and activity, implicating PARP1 as a therapeutic target to overcome tamoxifen resistance [19,20]. The gene discussed is PARP1; the disease is breast cancer.